Literature DB >> 36105340

Substituted 6,7-Dihydro-5H-Benzo[7]annulene Compounds as Selective Estrogen Receptor Degraders for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 36105340      PMCID： PMC9465704          DOI： 10.1021/acsmedchemlett.2c00342

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Accelerating drug development in breast cancer: New frontiers for ER inhibition.

Authors:  Emanuela Ferraro; Elaine M Walsh; Jacqueline J Tao; Sarat Chandarlapaty; Komal Jhaveri
Journal:  Cancer Treat Rev       Date:  2022-06-27       Impact factor: 13.608

Review 2.  Mechanistic insights expatiating the biological role and regulatory implications of estrogen and HER2 in breast cancer metastasis.

Authors:  Mohsin Ahmad Ghauri; Ali Raza; Uzma Hayat; Naveel Atif; Hafiz M N Iqbal; Muhammad Bilal
Journal:  Biochim Biophys Acta Gen Subj       Date:  2022-02-22       Impact factor: 3.770

Review 3.  Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update.

Authors:  Swati Sucharita Mohanty; Chita Ranjan Sahoo; Rabindra Nath Padhy
Journal:  Genes Dis       Date:  2020-12-17

Review 4.  The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives.

Authors:  Olga A Sukocheva; Elena Lukina; Markus Friedemann; Mario Menschikowski; Albert Hagelgans; Gjumrakch Aliev
Journal:  Semin Cancer Biol       Date:  2020-12-07       Impact factor: 15.707

Review 5.  ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.

Authors:  Jamie O Brett; Laura M Spring; Aditya Bardia; Seth A Wander
Journal:  Breast Cancer Res       Date:  2021-08-15       Impact factor: 6.466

Review 6.  Estrogen receptor-low breast cancer: Biology chaos and treatment paradox.

Authors:  Ke-Da Yu; Yu-Wen Cai; Song-Yang Wu; Ruo-Hong Shui; Zhi-Ming Shao
Journal:  Cancer Commun (Lond)       Date:  2021-07-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.